Pricing Log in Create free account
Friday 6 November 2026 Export PROF’s income statement to Excel — free account

Profound Medical

PROF Healthcare Medical Devices

Profound Medical’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, up 50.7% from fiscal 2024.

Revenue
+85.9%
EPS
+18.8%
Free cash flow
+47.9%
Total debt
+0.71%

Quarter to September 2026, against a year earlier

6.91 0.03 +0.44%
Market cap
$251.3M
P/E
0.0×
Fwd P/E
−7.8×
Dividend yield
—
F-score
4/9
Altman Z
7.27
Beneish M
−2.62
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 3.11%

Capital & Financial Ratios $m

Size
Market Cap 251.33
Revenue ttm 23.63
Net income ttm (32.49)
Free cash flow ttm (31.49)
Net debt Q (28.83)
Valuation
P/E 0.00
Forward P/E (7.78) (negative: loss-making)
Price / sales 10.63 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 5.91
Financial health
Current ratio Q 4.54 (at or above 1.5: strong)
Debt / equity Q 0.11 (at or below 0.5: strong)
Interest coverage Q 40.25
Growth
Revenue growth Q +85.86% (above 0%: growing)
Operating income growth Q +12.25% (above 0%: growing)
EPS, this year +41.61% (at or above 15%: strong)
EPS, next year A +25.71% (at or above 15%: strong)
Revenue, next year A +157.87% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +63.25% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 9.6×, against a ten-year median of 22.4×; over the ten years it ranged from 6.1× in 2022 to 50.6× in 2021.
P/S against its own 10 years 2.85%
10-year low 10-year high
P/B against its own 10 years 87.92%
10-year low 10-year high
EV/Sales against its own 10 years 10.34%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 26 55 60 33
Receivables 7 7 7 11
Inventory 7 6 8 10
Other — — — —
42 69 76 55
2023 2024 2025 Q'26
Payables 1 1 2 1
ST’ Debt 2 2 — 5
Other 2 3 4 6
6 7 6 12

Compound Annual Growth %

10y 5y 3y
Sales — 17.12% 34.06%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — (7.36%) 8.51%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.22 Actual −0.26

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.38 −0.26 Beat by 0.12
Q4 FY25 −0.27 −0.27 Met by 0.00
Q1 FY26 −0.24 −0.19 Beat by 0.05
Q2 FY26 −0.22 −0.26 Miss by 0.04
Q3 FY26 −0.19 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.19) (0.26) (0.21) — —
’25 (0.36) (0.52) (0.26) (0.27) (1.41)
’24 (0.26) (0.28) (0.38) (0.20) (1.12)
’23 (0.32) (0.35) (0.26) (0.42) (1.34)
’22 (0.40) (0.28) (0.24) (0.46) (1.38)
’21 (0.37) (0.35) (0.29) (0.49) (1.50)
’20 (0.19) (0.33) (0.32) (0.38) (1.25)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 5 2 10 — —
’25 3 2 5 6 16
’24 1 2 3 4 11
’23 2 2 2 2 7
’22 1 2 2 1 7
’21 1 3 3 1 7
’20 1 1 2 3 7
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (11) (5) — —
’25 (8) (14) (10) (7) (38)
’24 (5) (6) (7) (6) (23)
’23 (6) (5) (4) (7) (23)
’22 (8) (6) (6) (7) (26)
’21 (6) (6) (5) (5) (22)
’20 (7) (2) (4) (7) (21)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (11) (5) — —
’25 (8) (14) (10) (7) (38)
’24 (5) (6) (7) (6) (23)
’23 (6) (5) (4) (7) (23)
’22 (8) (6) (6) (7) (26)
’21 (6) (6) (5) (5) (23)
’20 (7) (2) (4) (8) (21)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 4 2 4 7 7 7 7 11 16 24 +19.3% 42 67 96 +81.4%
Gross margin, % 0.00 20.45 31.46 57.26 47.56 42.95 45.22 59.90 65.89 70.77 73.86 +70.8 pt
EBT (12) (15) (15) (15) (22) (31) (28) (28) (28) (42) (32) +14.7%
EBT margin, % 0.00 (387.44) (798.22) (361.16) (295.41) (445.13) (424.82) (395.21) (260.47) (262.88) (137.08) (262.9) pt
Net income (12) 0 0 (15) (22) (31) (29) (28) (28) (43) (32) +15.0%
Per share, $
Per share, $ Revenue 0.00 0.64 0.19 0.38 0.42 0.34 0.32 0.34 0.43 0.53 0.65 n/m
Earnings (2.89) (2.48) (1.52) (1.37) (1.25) (1.50) (1.38) (1.34) (1.12) (1.41) (0.93) (7.7%)
Cash flow (2.59) (1.94) (1.34) (1.36) (1.19) (1.09) (1.24) (1.07) (0.95) (1.26) (0.86) (7.7%)
Capex 0.00 0.00 0.00 (0.02) (0.02) (0.03) 0.00 0.00 0.00 (0.01) 0.00 n/m
Free cash flow (2.59) (1.94) (1.34) (1.37) (1.21) (1.12) (1.24) (1.07) (0.95) (1.27) (0.86) (7.6%)
Book value 2.65 1.84 1.95 1.29 5.63 3.94 2.50 1.47 2.44 2.20 1.16 (2.0%)
Shares, m 4 6 10 11 17 20 21 21 25 30 35 +24.7%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — 0.00 0.00 31.43 48.68 33.44 34.45 23.39 17.42 14.78 10.63 22.6
P/B — 0.00 0.00 29.38 3.65 2.85 4.43 5.39 3.08 3.58 5.91 5.8
EV/Sales — 0.00 0.00 30.05 37.43 23.87 28.56 20.74 12.71 11.63 9.60 18.3
EV/FCF — 0.00 0.00 0.00 (13.29) (7.15) (7.23) (6.43) (5.65) (4.82) (7.06) (5.0)
Cash, $m
Cash, $m Operating cash flow (11) (12) (13) (15) (21) (22) (26) (23) (23) (38) (31) +15.1%
Capex (1) 0 — 0 0 (1) — — — 0 (1) (12.5%)
Free cash flow (11) (12) (13) (15) (21) (23) (26) (23) (23) (38) (31) +15.2%
Balance, $m
Balance, $m Working capital 13 6 22 15 93 73 58 36 63 70 43 +20.6%
Net debt (10) (5) (14) (6) (82) (66) (39) (19) (50) (55) (29) +20.4%
Shareholders’ equity 11 11 20 14 97 81 52 31 60 66 43 +22.1%
Returns, %
Returns, % ROA (60.69) (171.60) 0.00 (63.94) (32.11) (32.08) (37.92) (52.27) (48.72) (57.64) (64.68) +3.0 pt
ROIC 0.00 0.00 0.00 (107.00) (77.98) (127.61) (158.59) (147.81) (203.16) (230.01) (156.58) (230.0) pt
ROE (108.45) (135.03) (98.84) (89.68) (38.71) (34.50) (43.23) (68.06) (60.70) (67.12) (87.04) +41.3 pt
People
People Employees — — 67 75 109 109 131 131 142 162 — +13.4%
Revenue/emp, $m — 0.00 0.03 0.06 0.07 0.06 0.05 0.05 0.08 0.10 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Profound Medical vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CLPT ClearPoint Neuro, Inc. $278.6M — (loss-making) — (loss-making) +36.27% (above 0%: growing) n/m −58.10% (below 0%: shrinking) 58.46% (52.44%) Compare
TMCI Treace Medical Concepts, Inc. $271.9M — (loss-making) — (loss-making) −4.24% (below 0%: shrinking) n/m +11.74% (above 0%: growing) 78.47% (32.96%) Compare
INFU InfuSystems Holdings, Inc. $270.1M 32.0× 33.0× +2.59% (above 0%: growing) +33.33% (above 0%: growing) −66.54% (below 0%: shrinking) 57.98% 11.24% Compare
QSI Quantum-Si Incorporated $256.1M — (loss-making) — (loss-making) −61.59% (below 0%: shrinking) n/m +37.48% (above 0%: growing) 34.91% (11,215.09%) Compare
PROF Profound Medical $251.3M — (loss-making) — (loss-making) +85.86% (above 0%: growing) n/m +47.93% (above 0%: growing) 78.13% (79.56%)
LAB Standard BioTools Inc. $245.7M 1.8× — (loss-making) −0.85% (below 0%: shrinking) n/m +73.32% (above 0%: growing) 55.86% (101.98%) Compare
ELMD Electromed, Inc. $221.8M 19.4× 18.6× +11.64% (above 0%: growing) +57.69% (above 0%: growing) −25.15% (below 0%: shrinking) 78.71% 19.70% Compare
TLSI TriSalus Life Sciences, Inc. $217.4M — (loss-making) — (loss-making) +1.73% (above 0%: growing) n/m −41.29% (below 0%: shrinking) 86.78% (86.03%) Compare
RXST RxSight, Inc. $190.4M — (loss-making) — (loss-making) −18.97% (below 0%: shrinking) n/m +2,591.06% (above 0%: growing) 73.62% (75.32%) Compare
Median of peers $250.9M 19.4× — +0.44% — −6.70% 66.04% (63.88%)

All 149 Medical Devices stocks →

Profound Medical (PROF) Latest News

6 Nov

Impact 4 · · The Motley Fool transcript
Impact 3 · · MarketBeat transcript
Impact 3 · · GuruFocus.com transcript

5 Nov

Impact 3 · · GlobeNewswire

30 Oct

Impact 3 · · GlobeNewswire

22 Oct

Impact 3 · · GlobeNewswire

14 Oct

Impact 4 · · GlobeNewswire
Impact 3 ·

9 Oct

Impact 4 · · GlobeNewswire
Impact 4 · · Zacks

7 Oct

Impact 4 · · GlobeNewswire

17 Aug

Impact 4 ·

13 Aug

Impact 3 · · The Motley Fool transcript

7 Aug

Impact 4 · transcript
Impact 3 · · Moby transcript
Impact 3 · · MarketBeat

6 Aug

Impact 3 ·
Impact 3 ·

24 Jul

Impact 3 ·

8 May

Impact 4 · · MarketBeat

7 May

Impact 4 · · MT Newswires
Impact 4 · · GlobeNewswire

3 May

Impact 4 · · Simply Wall St.

25 Apr

Impact 4 · · MarketBeat

1 Apr

Impact 3 · · GlobeNewswire

14 Mar

Impact 4 · · TipRanks

13 Mar

Impact 4 · · GlobeNewswire

9 Mar

Impact 4 · · GlobeNewswire

6 Mar

Impact 4 · · GuruFocus.com

5 Mar

Impact 4 · · MarketBeat
stockrow.com/PROF · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com